Diagnostic and therapeutic advances in the cardiovascular field have caused a progressive reduction in mortality from acute causes, with an ever-increasing chronicity of cardiovascular pathologies. In recent years, mechanical supports have played a fundamental role, allowing the patient to be stabilized in the most critical phase of acute heart failure (AHF) and acting as a "bridge" for definitive therapies. Heart transplantation (HTx) is the gold-standard treatment for end-stage HF, but it is burdened by a series of critical issues that limit its use, first of all the shortage of grafts. It also requires the patient to take immunosuppressive therapy for life, which exposes him to a greater risk of infectious and oncological diseases. For these reasons, in the last years, mechanical supports are increasingly used as "destination therapy", alternatively to HTx. However, also mechanical supports are not free from critical issues that limit their use. In this review we aim to analyze critical issues and future perspectives of advanced HF therapies.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.cpcardiol.2024.102971 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!